NovoCure
NVCR
318 hedge funds and large institutions have $9.02B invested in NovoCure in 2021 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 107 increasing their positions, 114 reducing their positions, and 81 closing their positions.
0.3% less ownership
Funds ownership: 75.16% → 74.86% (-0.3%)
6% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 114
12% less funds holding
Funds holding: 362 → 318 (-44)
29% less call options, than puts
Call options by funds: $136M | Put options by funds: $192M
48% less capital invested
Capital invested by funds: $17.2B → $9.02B (-$8.22B)
49% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 81
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$214M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$117M |
| 3 |
Two Sigma Investments
New York
|
+$35.8M |
| 4 |
BlackRock
New York
|
+$30.8M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$203M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$76.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$65M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$36.5M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$25.4M |
NVCR Hedge Fund Activity: Q3 2021 in Review
318 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2021, worth a combined $9.02B — down 48% from $17.2B a quarter earlier.
Sellers outnumbered buyers: 81 funds closed out of NVCR and 41 opened new positions — a net loss of 40 holders — while 114 trimmed existing stakes and 107 added.
The largest buyer was Capital International Investors, adding an estimated $214M. The largest seller was Fidelity Investments, cutting an estimated $203M.
- 318 institutional investors held NovoCure (NVCR) as of Q3 2021, down from 362 in Q2 2021.
- Funds reported $9.02B of NovoCure stock for Q3 2021, down 48% quarter-over-quarter.
- 41 funds opened new NovoCure positions in Q3 2021 and 81 closed out, a net change of -40 holders.
- The largest NovoCure buyer in Q3 2021 was Capital International Investors, an estimated $214M added.
- The largest NovoCure seller in Q3 2021 was Fidelity Investments, an estimated $203M sold.
Based on aggregated 13F filings for Q3 2021.